» Articles » PMID: 32899435

Quercetin As an Agent for Protecting the Bone: A Review of the Current Evidence

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Sep 9
PMID 32899435
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Quercetin is a flavonoid abundantly found in fruits and vegetables. It possesses a wide spectrum of biological activities, thus suggesting a role in disease prevention and health promotion. The present review aimed to uncover the bone-sparing effects of quercetin and its mechanism of action. Animal studies have found that the action of quercetin on bone is largely protective, with a small number of studies reporting negative outcomes. Quercetin was shown to inhibit RANKL-mediated osteoclastogenesis, osteoblast apoptosis, oxidative stress and inflammatory response while promoting osteogenesis, angiogenesis, antioxidant expression, adipocyte apoptosis and osteoclast apoptosis. The possible underlying mechanisms involved are regulation of Wnt, NF-κB, Nrf2, SMAD-dependent, and intrinsic and extrinsic apoptotic pathways. On the other hand, quercetin was shown to exert complex and competing actions on the MAPK signalling pathway to orchestrate bone metabolism, resulting in both stimulatory and inhibitory effects on bone in parallel. The overall interaction is believed to result in a positive effect on bone. Considering the important contributions of quercetin in regulating bone homeostasis, it may be considered an economical and promising agent for improving bone health. The documented preclinical findings await further validation from human clinical trials.

Citing Articles

Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women.

Bailly A, Hester G, Alesi M, Buresh R, Feito Y, Mermier C J Bone Miner Metab. 2025; .

PMID: 40053115 DOI: 10.1007/s00774-025-01592-0.


New Insights in Natural Bioactive Compounds for Periodontal Disease: Advanced Molecular Mechanisms and Therapeutic Potential.

Hashim N, Babiker R, Chaitanya N, Mohammed R, Priya S, Padmanabhan V Molecules. 2025; 30(4).

PMID: 40005119 PMC: 11858609. DOI: 10.3390/molecules30040807.


The Preventive Impact of Chokeberry ( L.) Extract Regarding the Disruption of Calcium and Phosphorus Homeostasis and Chosen Pathways of Its Regulation in an Animal Model of General Population Exposure to Cadmium.

Brzoska M, Galazyn-Sidorczuk M, Rogalska J Nutrients. 2025; 17(4).

PMID: 40005030 PMC: 11858106. DOI: 10.3390/nu17040702.


Exploring the Potential of in Managing Bone Loss: Insights from Preclinical Studies.

Hairi H, Jusoh R, Sadikan M, Hasan W, Shuid A Int J Med Sci. 2025; 22(4):819-833.

PMID: 39991771 PMC: 11843146. DOI: 10.7150/ijms.103241.


Nrf2 Activation as a Therapeutic Target for Flavonoids in Aging-Related Osteoporosis.

Messeha S, Fidudusola F, Gendy S, Latinwo L, Odewumi C, Soliman K Nutrients. 2025; 17(2).

PMID: 39861398 PMC: 11767473. DOI: 10.3390/nu17020267.


References
1.
Paulke A, Eckert G, Schubert-Zsilavecz M, Wurglics M . Isoquercitrin provides better bioavailability than quercetin: comparison of quercetin metabolites in body tissue and brain sections after six days administration of isoquercitrin and quercetin. Pharmazie. 2013; 67(12):991-6. View

2.
Kanter M, Altan M, Donmez S, Ocakci A, Kartal M . The effects of quercetin on bone minerals, biomechanical behavior, and structure in streptozotocin-induced diabetic rats. Cell Biochem Funct. 2007; 25(6):747-52. DOI: 10.1002/cbf.1397. View

3.
Redlich K, Smolen J . Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012; 11(3):234-50. DOI: 10.1038/nrd3669. View

4.
Deshmukh P, Unni S, Krishnappa G, Padmanabhan B . The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017; 9(1):41-56. PMC: 5425799. DOI: 10.1007/s12551-016-0244-4. View

5.
Derakhshanian H, Djalali M, Djazayery A, Nourijelyani K, Ghadbeigi S, Pishva H . Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate. Can J Physiol Pharmacol. 2013; 91(5):380-5. DOI: 10.1139/cjpp-2012-0190. View